MEDFORD, N.Y., April 1, 2016 -- Korbin Forrister is an adventurous athlete with a passion for giving back. Since he was kindergarten age, Korbin could be found racing on the dirt track – and consistently leading the pack. During his extensive career, he's shifted from dirt tracks to asphalt and is adept at racing on both. Now he's a fan favorite in both the ARCA series and the NASCAR truck series. Forrister has his eyes firmly on making his way up to the NASCAR Sprint Cup Series while stopping along the way to lend a helping hand to charities that help critically ill children, rescue animals, and American veterans. Korbin believes that being a true success in life requires a person to become involved in bettering their local community and the world.
Korbin is strong supporter of Canine Companions for Independence, the nation's largest provider of highly trained assistance dogs to children and adults with disabilities. What do race cars and assistance dogs have in common? Performance! NASCAR drivers like Korbin want the best for their vehicles and people with disabilities need high performing assistance dogs. Korbin's love for dogs and wanting to help people with disabilities is a perfect match to partner with Canine Companions for Independence. "It's simply amazing what these Canine Companions for Independence dogs do for people with disabilities," says Korbin, "Helping Canine Companions be more recognizable with the public during my racing career is very exciting."
NASCAR fans attending the NY International Auto show at the Javits Center in Manhattan will get the chance to meet Korbin and see his #59 Lira Motorsports ARCA Truck Series F-150. Korbin will sign autographs Saturday, April 2nd- 10:30am- 11:30am, 2pm -3:30pm, and 6pm-7:30pm Ground Floor- Booth: #1200
|
||||||||||
For more information about Korbin Forrister, visit: http://www.korbinforrister.com/
Korbin's Next Race: April 29 Talladega ARCA 200
Contact: John Bentzinger [email protected] 516-330-6457
ABOUT CANINE COMPANIONS FOR INDEPENDENCE: Canine Companions for Independence is the largest non-profit provider of trained assistance dogs with six regional training centers across the country. Established in 1975, Canine Companions provides highly trained assistance dogs to children, adults and veterans with disabilities and is recognized worldwide for the excellence of its dogs, and quality and longevity of the matches it makes between dogs and people. There is no charge for the dog, its training and on-going follow-up services. For more information, visit cci.org or call 1-800-572-BARK.
Photos accompanying this release are available at:
http://www.globenewswire.com/newsroom/prs/?pkgid=39692
http://www.globenewswire.com/newsroom/prs/?pkgid=39693
CONTACT: John Bentzinger
[email protected]
516-330-6457


Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Washington Post Publisher Will Lewis Steps Down After Layoffs
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 



